Navigation Links
Immune responses to flu vaccine are diminished in lupus patients
Date:7/29/2009

Patients with the autoimmune disease systemic lupus erythematosus (SLE) have an increased risk of infection, due to both disturbances in their immune responses and treatment with immunosuppressive drugs. Because morbidity and mortality related to influenza are increased in immunocompromised patients, it is recommended that patients with SLE get annual flu shots, which are safe and do not increase disease activity. Both antibody and cell-mediated responses are involved in the immune response to influenza; in SLE, antibody responses to the vaccine are diminished, but it is not known if the same effect is seen in cell-mediated responses. A new study was the first to examine cell-mediated responses in SLE patients prior to and following influenza vaccination. The study was published in the August issue of Arthritis & Rheumatism (http://www.interscience.wiley.com/journal/arthritis).

Led by Albert Holvast, of the University of Groningen in The Netherlands, the study involved 54 patients with SLE and 54 healthy controls who received subunit flu vaccine, out of a total of 78 patients in each group. Patients were randomized 2:1 to receive a flu vaccine or serve as a nonvaccinated control. Patients and controls were followed up at 28 days and three to four months following vaccination, at which time blood was drawn.

Vaccination induces an influenza virus-specific immune response which is generally documented as the generation of antibodies specifically reacting with the virus. However, the main defense against the virus is exerted by specific immune cells, in particular CD4+ and CD8+ T-cells which are part of the immune response induced by vaccination. The level of this so-called cellular immune response has until now not been documented in patients with SLE, but is crucial for the effect of vaccination.

The results showed that cell-mediated responses (both CD4+ and CD8+ T-cells) to influenza were lower in SLE patients prior to vaccination. Following vaccination, cell-mediated responses remained lower in SLE patients than controls. CD4+ and CD8+ T-cell responses to staphylococcal enterotoxin B (SEB), which was used as a positive control, were normal in patients with SLE, indicating that their decreased cell-mediated response to the flu vaccine was not attributable to a decreased responsiveness of T cells in general. However, the use of the medications prednisone and/or azathioprine was associated with lower cell-mediated responses following vaccination.

Previous studies have shown that antibody production following flu vaccination is lower in SLE patients than in the general population and the current study confirmed these results. The authors evaluated the relationships between antibody and cell-mediated responses because CD4+ T-cell help is necessary for antibody responses. While they did not find a correlation between CD4+ T-cell and antibody responses using flow cytometry, they did find a modest correlation using ELISpot assay, a more sensitive technique. They also found that flu vaccination did not induce disease activity over three to four months.

Although the sample size in this study was not large, the authors conclude that the diminished cell-mediated immune and antibody responses to flu vaccination in SLE patients are representative of what occurs in daily practice. "Clinicians should be aware that this combined defect might increase the morbidity and mortality due to influenza virus infection, in particular in patients receiving prednisone and/or azathioprine," they state, adding that evaluating clinical protection against influenza in SLE patients following vaccination may be warranted in order to assess whether more effective influenza vaccines or vaccination strategies are warranted.


'/>"/>

Contact: Jennifer Beal
medicalnews@wiley.com
44-124-377-0633
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. Immune deficiency linked to a type of eye cancer
3. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
4. Melanoma drug revs immune cells but cancer cells ignore it
5. Study identifies key player in the bodys immune response to chronic stress
6. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
7. UVA researchers find important clue to immune infertility
8. M.D. Anderson-led team reports possible key to autoimmune disease
9. Their immune cells, fighting your cancer
10. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
11. Occupational exposures may be linked to death from autoimmune disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
(Date:2/12/2016)... ... February 12, 2016 , ... As a former television executive, owner ... job, and no time to decompress, Rabinowitz found herself drawn to a casual meditation ... its impact on her life, implementing a 20-minute-per-day meditation practice with her team. After ...
(Date:2/12/2016)... ... 12, 2016 , ... Every winter, someone is killed, injured or loses a ... Burn Center, part of the Allegheny Health Network, has partnered with Etna Volunteer ... Heaters Need Space” campaign. , “Space Heaters Need Space” aims to bring ...
(Date:2/12/2016)... Columbus, OH (PRWEB) , ... February 12, 2016 , ... ... families of the greater Columbus, OH area. The latest campaign focuses on the fight ... the disease. Donations are now being accepted here . , Carmen is a ...
(Date:2/12/2016)... ... February 12, 2016 , ... J Thomas ... by continuing it’s commitment to act as Agents of Change in the community, ... with area homeless families to fulfill immediate needs and help them move into ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... --> ... Global Clinical Trials Review, H2, 2015 provides an ... trials landscape along with top level data related ... & E7), Trial Status, Trial Phase, Sponsor Type ... involved and enlists all trials (Trial title, Phase, ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary ... and future adoption patterns on the usage of liquid ... the following: - Timeframe of liquid biopsy ... ctDNA, cfDNA and Evs—by organization type - Sample inflow ... types: blood, saliva, stool, serum, and so on. - ...
(Date:2/11/2016)... 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial ... 2015. The Company also filed its Quarterly Report on Form ... the Securities and Exchange Commission today. --> ... --> --> Net sales for ... or 95%, to $5.4 million from $2.8 million for the ...
Breaking Medicine Technology: